These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206 [TBL] [Abstract][Full Text] [Related]
5. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486 [TBL] [Abstract][Full Text] [Related]
6. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001 [TBL] [Abstract][Full Text] [Related]
7. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977 [TBL] [Abstract][Full Text] [Related]
8. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy Fan B; Zheng X; Wang Y; Hu X Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269 [No Abstract] [Full Text] [Related]
9. Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. de Jong FC; Rutten VC; Zuiverloon TCM; Theodorescu D Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802033 [TBL] [Abstract][Full Text] [Related]
11. [Detection of peripheral follicular helper T cells in rheumatoid arthritis]. An LM; Li J; Ji LL; Li GT; Zhang ZL Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):951-957. PubMed ID: 27987496 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
13. Follicular helper T cells promote the effector functions of CD8 Shi W; Dong L; Sun Q; Ding H; Meng J; Dai G Exp Cell Res; 2018 Nov; 372(1):35-42. PubMed ID: 30205088 [TBL] [Abstract][Full Text] [Related]
15. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296 [TBL] [Abstract][Full Text] [Related]
16. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Noël G; Fontsa ML; Garaud S; De Silva P; de Wind A; Van den Eynden GG; Salgado R; Boisson A; Locy H; Thomas N; Solinas C; Migliori E; Naveaux C; Duvillier H; Lucas S; Craciun L; Thielemans K; Larsimont D; Willard-Gallo K J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411002 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral CXCL13 Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528 [TBL] [Abstract][Full Text] [Related]
18. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065 [TBL] [Abstract][Full Text] [Related]
19. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250 [TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function. Brunet-Ratnasingham E; Morou A; Dubé M; Niessl J; Baxter AE; Tastet O; Brassard N; Ortega-Delgado G; Charlebois R; Freeman GJ; Tremblay C; Routy JP; Kaufmann DE EBioMedicine; 2022 Oct; 84():104254. PubMed ID: 36150362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]